CA2330139A1 - Compositions a base de r-rabeprazole et procedes - Google Patents

Compositions a base de r-rabeprazole et procedes Download PDF

Info

Publication number
CA2330139A1
CA2330139A1 CA002330139A CA2330139A CA2330139A1 CA 2330139 A1 CA2330139 A1 CA 2330139A1 CA 002330139 A CA002330139 A CA 002330139A CA 2330139 A CA2330139 A CA 2330139A CA 2330139 A1 CA2330139 A1 CA 2330139A1
Authority
CA
Canada
Prior art keywords
rabeprazole
pharmaceutically acceptable
acceptable salt
treating
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330139A
Other languages
English (en)
Inventor
William E. Yelle
Paul D. Rubin
Patrick Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2330139A1 publication Critical patent/CA2330139A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés et des compositions dont le principe repose sur l'utilisation du produit optiquement pur R (+) rabéprazole, qui permet de traiter les ulcères chez l'homme tout en réduisant sensiblement le risque concomitant des effets néfastes associés au conglomérat racémique de rabéprazole. L'isomère optiquement pur R (+) est également utile pour le traitement du reflux gastro-oesophagien. En tant qu'inhibiteur de la libération de H?+¿, le R (+) rabéprazole intervient utilement dans le traitement d'autres affections liées à l'hypersécrétion gastrique, comme par exemple le syndrome de Zollinger-Ellison.
CA002330139A 1998-04-30 1999-04-28 Compositions a base de r-rabeprazole et procedes Abandoned CA2330139A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372598P 1998-04-30 1998-04-30
US60/083,725 1998-04-30
PCT/US1999/009205 WO1999055157A1 (fr) 1998-04-30 1999-04-28 Compositions a base de r-rabeprazole et procedes

Publications (1)

Publication Number Publication Date
CA2330139A1 true CA2330139A1 (fr) 1999-11-04

Family

ID=22180277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330139A Abandoned CA2330139A1 (fr) 1998-04-30 1999-04-28 Compositions a base de r-rabeprazole et procedes

Country Status (5)

Country Link
EP (1) EP1073332A4 (fr)
JP (1) JP2002512262A (fr)
AU (1) AU3870599A (fr)
CA (1) CA2330139A1 (fr)
WO (1) WO1999055157A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097753A2 (fr) * 2000-06-19 2001-12-27 Eisai Co. Ltd. Nouvelles methodes utilisant des derives de pyridine
JP2013529623A (ja) 2010-06-24 2013-07-22 シプラ・リミテッド デクスラベプラゾールの塩及び多形体
CN105395490B (zh) * 2014-08-23 2018-04-03 南京海纳医药科技股份有限公司 一种含右旋雷贝拉唑钠药物组合物冻干粉针及其制备方法
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH07278141A (ja) * 1994-01-12 1995-10-24 Eisai Co Ltd 光学活性ベンズイミダゾール誘導体の製造法および中間体
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung

Also Published As

Publication number Publication date
JP2002512262A (ja) 2002-04-23
AU3870599A (en) 1999-11-16
WO1999055157A1 (fr) 1999-11-04
EP1073332A1 (fr) 2001-02-07
EP1073332A4 (fr) 2005-06-15

Similar Documents

Publication Publication Date Title
US20050222211A1 (en) S(-)rabeprazole compositions and methods
AU742620B2 (en) R-lansoprazole compositions and methods
US20010025107A1 (en) S-lansoprazole compositions and methods
US6174902B1 (en) R-rabeprazole compositions and methods
CA2161130A1 (fr) Methodes et compositions pour le traitement de troubles gastriques grace a du (+) pantoprazole optiquement pur
CA2330139A1 (fr) Compositions a base de r-rabeprazole et procedes
EP1082114B1 (fr) Compositions d'hydroxymeprazole et leurs utilisations
AU2003257509A1 (en) S-rabeprazole compositions and methods
AU2003268822A1 (en) R-raberprazole compositions and methods
EP1098648B1 (fr) Compositions pharmaceutiques contenant de l'hydroxylansoprazole et utilisations de ces dernieres
US20040224989A1 (en) S-lansoprazole compositions and methods
AU2003264624A1 (en) S-lansoprazole compositions and methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead